# Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07807384` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07807384](<https://clinicaltrials.gov/study/NCT07807384>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07807384

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 115 participants.

## Technical summary

Registry record NCT07807384. Allocation not applicable; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 115 participants (planned count; ClinicalTrials.gov record NCT07807384, source copy `cardio:ctgov-nct07807384-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07807384, source copy `cardio:ctgov-nct07807384-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07807384, source copy `cardio:ctgov-nct07807384-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07807384, source copy `cardio:ctgov-nct07807384-2026-11-12`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07807384-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug): Mavacamten
- Lead sponsor: Second Affiliated Hospital of Nanchang University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Mavacamten (`cardio:mavacamten`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital of Nanchang University (`cardio:org-second-affiliated-hospital-of-nanchang-university`)

## Provenance

Content hash: c50541e08915a0240edd2b85df84196ee190a8c7eebe3e9cb23549192a165bcd
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
